LYON, France -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, today announces it is actively participating in the Societe Internationale d'Urologie (SIU) Conference to be held in Cape Town, South Africa November 12-16. EDAP Chief Operating Officer Marc Oczachowski as well as members of the sales staff are attending. EDAP's distributor in the market, Intamarket, is attending as well.

EDAP will also participate in the upcoming French Association of Urology Meeting to be held November 29 to December 2. Additional information on EDAP's activities around this event will be available later.

At the SIU meeting, Dr. Stefan Thuroff of Harlaching Hospital, Munich, Germany, is presenting several items including a comparison of HIFU technology available in the prostate cancer marketplace, a study of patients with primary metastatic prostate cancer achieving complete remission after HIFU therapy, a paper detailed the benefits of the Ablatherm with Integrated Imaging for urologists in treating nonsurgical patients and a study detailing the low side effects recorded using HIFU for primary treatment, retreatment and salvage therapy cases. Dr Thuroff is also presenting a complete video program on HIFU detailing its use in treating localized prostate cancer, efficacy, low side effect and the technological development of the Ablatherm-HIFU device.

"We are pleased to continue reaching out to doctors through conference events where we can display the strong clinical experience behind the Ablatherm-HIFU device," said Oczachowski. "These events bring together top urologists from around the world to learn about the new options available in treating this disease, and HIFU is clearly gaining prestige as a new and potentially attractive therapy for patients concerned about preserving quality of life. EDAP's clinical background and strong user base set it apart as an established and clearly documented option for these patients, which is driving increased interest in the medical community around the globe."

"We continue to develop the clinical base for the Ablatherm and the various scientific publications on Ablatherm-HIFU presented during this event bring additional credibility to Ablatherm," said Thuroff. "As early adopter of HIFU, I see growing interest in HIFU therapy from urologists seeking to provide for their patients' increasing demands for minimally invasive therapies without such side effects as are common from traditional treatments; and this is based on Ablatherm-HIFU scientific background."

"We look forward to the upcoming conference events as they lay the foundation of awareness for HIFU therapy among urologists," said Hugues de Bantel, CEO of EDAP TMS S.A. "The SIU is an excellent event and approximately 3,000 urologists from around the world registered this year. We also look forward to the French congress and our opportunity to address our growing base in our home country. Ablatherm continues to grow in France even prior to the reimbursement approval being secured, a strong testament to its value in urology. We enjoy excellent support from the urologists in bringing Ablatherm to France as a primary treatment choice of the future as well as to securing a successful reimbursement program to make this therapy available to men seeking effective treatment without giving up quality of life."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Halliburton Investor Relations at (972) 458-8000, the Corporate Investor Relations Dept at +33 (0) 4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com.